Q-omics provides the consensus-scored MIR6081 profile across patient tissues and cancer cell-line models. MIR6081 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MIR6081 is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, MIR6081 RNA expression shows 10,689 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight COAD, LUAD, and CCRCC as cancer lineages where MIR6081 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6081 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6081 survival associations across molecular data types. MIR6081 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6081 RNA expression–survival associations across cancer types. High MIR6081 expression shows unfavorable associations in COAD, READ, MESO, ACC, SKCM and KIRP. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for MIR6081 RNA expression.
This table summarizes MIR6081 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6081. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6081 shows higher tumor expression in LUAD and LUSC. The LUAD box plot shows higher MIR6081 RNA expression in tumor versus normal tissue (log2 FC = +0.347, t-test p = .011).
This table shows molecular features associated with MIR6081 in patient tissues and cancer cell lines. In patient samples, MIR6081 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
